SEC Form 4 · accession 0001209191-16-126674
Dimension Therapeutics, Inc. · DMTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
K. Reed Clark
Officer — SVP of Pharmaceutical Develop
Period of report
Jun 7, 2016
Accepted (ET)
Jun 8, 2016 · 8:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001592288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 7, 2016 | M | 5,000 | $0.38 | A | 5,000 | D | |
| Common Stock | Jun 7, 2016 | S | 5,000 | $10.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.38 | Jun 7, 2016 | M | 5,000 | D | — | Apr 21, 2024 | Common Stock | 5,000 | 114,739 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3This stock option vests over four (4) years beginning on April 1, 2014, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter.